Please assess the completion status of the following clinical trial:

Trial Title: BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* At least 5 years of age~* A clinical diagnosis of early M. ulcerans disease including:~  * Nodules~ * Plaques and small ulcers with or without oedema and less than or equal to 10cm in maximum diameter~ * Disease duration no longer than six months~ * DRB-PCR positive for M. ulcerans~Exclusion Criteria:~* Treatment with macrolide or quinolone antibiotics, or antituberculous medication, or immunomodulatory drugs including corticosteroids within the previous one month.~* Current treatment with any drugs likely to interact with the study medication, e.g, anticoagulants, cyclosporin, phenytoin, oral contraceptive, and phenobarbitone.~* History of hypersensitivity to rifampicin, streptomycin and or clarithromycin.~* History or having current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and immune compromise; or evidence for past or present tuberculosis.~* Pregnancy~* Inability to take oral medication or having gastrointestinal disease likely to interfere with drug absorption.~* Excessive alcohol intake.~* Any situation or condition which may compromise ability to comply with the trial procedures.~* Lack of willingness to give informed consent (and/or assent by parent/legal representative).

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SR4/CR4 (Type: EXPERIMENTAL): after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
- SR8 (Type: ACTIVE_COMPARATOR): standard treatment consisting of 8 weeks of streptomycin and rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).